Key Challenges Significant demand puts pressure on supply chain Ready-to-Use (RTU) primary packaging availability is critical to ensure clinical supplies and scale-up Mitigate risks from development to commercial Time to market is a key variable to seize the opportunity Minimize drug product wastage Fixed vs variable dose - single or multiple injections To follow patient preferences across geographies, both pens and auto-injectors are viable GLP-1 wide Stevanato Group is the right partner for GLP-1 & Peptides through our integrated offering Stevanato Group can serve GLP-1 & Peptides production processes with comprehensive solutions covering the full pharma value chain
Krbling M, Przepiorka S, Engel H, van Besien K, Giralt S, Andersson B, Huh Y, Deisseroth A, Andreeff M , Champlin R
Be careful of a Hy in Dry situation
They can advise you on which IV drip is best for you, with over 100 fresh and active ingredients available to be delivered directly to your body, tailor-made to your needs
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
Its currently on sale at Nordstrom and Amazon (with a coupon!) for the lowest price its been in weeks
